- $221.21m
- $154.31m
- $408.52m
Brief: Nevro Responds To Competitor's Announcement Of FDA Approval For Painful Diabetic Neuropathy
Brief: Nevro Announces FDA Approval For Expanded Labeling Of 10 KHZ High Frequency Spinal Cord Stimulation System
U.S. RESEARCH ROUNDUP-Apria, Doordash, Zymergen
U.S. STOCKS ON THE MOVE-Tilray, Moderna, Novavax, WeWork, Big Tech
U.S. STOCKS ON THE MOVE-Tesla, Dell, Citi Trends, Tilly's, Century Therapeutics
Nevro gains on upbeat revenue forecast
Brief: Nevro Announces Preliminary, Unaudited Fourth Quarter And Full-Year 2021 Revenue
U.S. STOCKS ON THE MOVE-GameStop, Exscientia, Marin Software
Nevro rises on UNH coverage for diabetes-related chronic pain therapy
Brief: Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy
Brief: Nevro Announces Settlement Of IP Litigation With Nalu Medical
NYSE ORDER IMBALANCE 130619.0 SHARES ON BUY SIDE
Brief: Nevro Announces Three Important Clinical Data Publications For Treating Painful Diabetic Neuropathy With 10 Khz Therapy
Nevro Corp reports results for the quarter ended in September - Earnings Summary
Brief: Nevro Provides Fourth Quarter Guidance
Brief: Nevro Announces Update In Patent Litigation With Boston Scientific
U.S. STOCKS ON THE MOVE-Fiverr International, Fastly, HanesBrands
U.S. STOCKS ON THE MOVE-Nevro, Fiverr International, MicroVision
U.S. STOCKS ON THE MOVE-Nevro, MicroVision, Roku